Last reviewed · How we verify
NCT00092027
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
Phase 3 trial testing MK0217, alendronate sodium/Duration of Treatment: 6 months in Postmenopausal Osteoporosis in 454 participants. Completed in 15 March 2004.
15 March 2004
Quick facts
| Lead sponsor | Organon and Co |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 454 |
| Start date | 19 March 2003 |
| Primary completion | 15 March 2004 |
| Estimated completion | 15 March 2004 |
Drugs / interventions tested
- MK0217, alendronate sodium/Duration of Treatment: 6 months — full drug profile →
- Comparator: placebo / Duration of Treatment: 6 months — full drug profile →
Conditions studied
- Postmenopausal Osteoporosis — all drugs for Postmenopausal Osteoporosis →
Sponsor
Organon and Co — full company profile →
Who can join
25 and older, female only, with Postmenopausal Osteoporosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is to assess the safety and tolerability of MK0217 being evaluated to treat women with postmenopausal osteoporosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00092027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postmenopausal Osteoporosis
Currently open trials in the same condition.
- NCT05010590 — Anabolic Therapy in Postmenopausal Osteoporosis · Phase 4 · active not recruiting
- NCT02822378 — Dried Plums and Bone Health in Postmenopausal Women · NA · active not recruiting
Other Organon and Co trials
Trials by the same sponsor.
- NCT05761444 — Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients · Phase 4 · completed
- NCT05789576 — A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Regi · Phase 4 · completed
- NCT05680740 — A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis · Phase 4 · completed
- NCT05560646 — A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 · Phase 2 · completed
- NCT05264506 — Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00092027 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Organon and Co
- Last refreshed: 14 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00092027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing